Showing 4911-4920 of 8786 results for "".
- Galderma's New Face for Change Program Supports Dress for Success, Skin Cancer Foundationhttps://practicaldermatology.com/news/galdermas-new-face-for-change-program-supports-dress-for-success-skin-cancer-foundation/2460668/Galderma is launching Face for Change, a program in partnership with Dress for Success and The Skin Cancer Foundation that will allow Dysport users to give back with each treatment. Starting January 19, 2021 and ending February 28, 2021, Galderma will contribute $100
- Pulse Biosciences Scores CE Mark for CellFX Systemhttps://practicaldermatology.com/news/pulse-biosciences-scores-ce-mark-for-cellfx-system/2460666/Pulse Biosciences, Inc. received CE mark for the CellFXSystem. The Company can now proceed with its planned controlled launch of the CellFX System to medical practices within the European Union (EU) for the treatment of general dermatologic conditions, including sebaceous hyperplasia (S
- Candela Launches Frax Pro Systemhttps://practicaldermatology.com/news/candela-launches-frax-pro-system/2460665/Candela’s Frax Pro system is now available. This platform features Frax 1550 and the novel Frax 1940 applicators. The Frax 1940 handpiece delivers a 1940 nm wavelength laser beam for a shallow, epidermal approach, with focal reach extending to approximately 200 μm in
- Arcutis Moves Another Candidate Into Phase 3 Trialshttps://practicaldermatology.com/news/arcutis-moves-another-candidate-into-phase-3-trials/2460664/Roughly a week after announcing plans to initiate Phase 3 clinical trials for topical roflumilast cream (ARQ-151) in the treatment of atopic dermatitis (AD),
- LEO Pharma Data: Tralokinumab Benefits Adult ADhttps://practicaldermatology.com/news/leo-pharma/2460662/Results from a post-hoc subanalysis of the Phase 3 ECZTRA 3 trial demonstrate the potential for LEO Pharma’s tralokinumab as a treatment for adults with moderate-to-severe atopic dermatitis. Investigational tralokinumab has not y
- Verrica: Post-Hoc Analyses Show Benefits of VP-102 at Specific Siteshttps://practicaldermatology.com/news/verrica-post-hoc-analyses-show-benefits-of-vp-102-at-specific-sites/2460661/Positive data from post-hoc pooled analyses of the pivotal Phase 3 CAMP trials demonstrate the safety and efficacy of Verrica Pharmaceuticals’ lead product candidate VP-102 in molluscum contagiosum (molluscum) in specific body regions. The data were presented in poster format online for the
- SBS Part 1: The Medical Dermatology Summit to Kick Off February 4https://practicaldermatology.com/news/sbs-part-1-the-medical-dermatology-summit-to-kick-off-february-4/2460659/SBS Part I: The Medical Dermatology Summit will offer complimentary direct access to leading academic experts, clinical leaders, researchers, and more through live-streamed and interactive sessions as well as on-deman
- Cyspera Demonstrates Efficacy, Safety in Three Published Studieshttps://practicaldermatology.com/news/cyspera-demonstrates-efficacy-safety-in-three-published-studies/2460657/Several studies recently published in peer reviewed journals demonstrate the safety and efficacy of stabilized-cysteamine 5% cream (Cyspera), the novel, non-hydroquinone, topical pigment regulator from Scientis In a randomized, double-blinded study of 50 melasma patients assigned to eit
- Arcutis Starts Phase 3 Trials of Topical Roflumilast Cream for ADhttps://practicaldermatology.com/news/arcutis-starts-phase-3-trials-of-topical-roflumilast-cream-for-ad/2460654/Arcutis Biotherapeutics, Inc. is starting their pivotal Phase 3 clinical trials evaluating topical roflumilast cream (ARQ-151) as a potential treatment for atopic dermatitis (AD). Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and s
- Fitness Level Tied to Psoriasis Riskhttps://practicaldermatology.com/news/fitness-level-tied-to-psoriasis-risk/2460653/Low fitness levels may increase risk for psoriasis, according to a register-based study of military recruits. Specifically, male recruits to compulsory military training who were rated as the least fit had a 35 percent higher risk for psoriasis when compared to the f